Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2014

View Archived Issues

Alzheimer's disease organizations fund drug repurposing studies

Scientists at M2i Development disclose novel diagnostic agents

Array BioPharma grants Oncothyreon exclusive license to ONT-380

Galapagos selects GLPG-2222 as part of its triple combination therapy for cystic fibrosis

Alnylam initiates phase III trial of revusiran in transthyretin-mediated amyloidotic cardiomyopathy

Novel JAK2 inhibitor NVP-CHZ868 displays potent activity in vitro and in murine MPN models

Hutchison MediPharma initiates phase III trial of fruquintinib in colorectal cancer

Inhibition of EZH2 leads to tumor growth inhibition in B-cell lymphoma cell lines

Study describes levels of biomarker of brain insulin resistance in hippocampal regions

Animal model of osteochondromagenesis highlights role of NFATc1

Kolltan Pharmaceuticals describes anti-SCFR monoclonal antibody

Antitumor activity seen with HER2-T-cell-dependent bispecific antibody developed at Genentech

BioCryst begins phase I trial of BCX-4430 for hemorrhagic fever viruses

Synageva BioPharma confirms active IND application for SBC-103

Novel CXCR-7 modulators disclosed by Actelion Pharmaceuticals

Cephalon divulges novel ALK inhibitors for cancer

Taiho Pharmaceutical patents novel compounds for urinary incontinence

Teijin Pharma reports new XO inhibitors

New company BliNK Biomedical created to focus on antibody discovery

Anthera Pharmaceuticals licenses Japanese rights to blisibimod to Zenyaku Kogyo

New study evaluates dabigatran etexilate to prevent recurrent embolic stroke of undetermined source

NEOD-001 given FDA fast track designation for AL amyloidosis

IND accepted for ADXS-HPV plus MEDI-4736 in HPV-associated cancers

Neovacs' phase IIb trial of TNF-Kinoid in rheumatoid arthritis misses endpoint

FDA approves Signifor LAR for acromegaly

ViiV Healthcare applies for Japanese approval of dolutegravir/abacavir/lamivudine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...